Skip to main content
Equibles

AJANTPHARM · Ajanta Pharma Limited · Financials

Use AJANTPHARM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AJANTPHARM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,284.00 INR -40.00 (-1.20%) At close · Nov 13
Rebalance outlook locked
Market Cap
410.37B INR
Shares
124.96M
Volume · Nov 13 194.12K Avg daily vol (3M) 116.02K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
54.53B +17.3%
FY2026 Revenue FY2018–FY2026
Net Income
10.56B +14.7%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
5.29B -54.3%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 62.17B 54.53B 46.48B 42.09B 37.43B 33.41B 28.9B 25.88B 20.55B 21.31B
INR 1.81B 1.73B 1.44B 1.35B 1.31B 1.25B 1.16B 957.2M 720.8M 595.9M
INR 128.8M 161.1M 207.3M 72.1M 58.4M 102M 82.7M 119.1M 11.6M 4.1M
INR 16.88B 13.78B 11.89B 11.14B 7.45B 9.09B 9B 6.64B 5.14B 6.23B
INR 4.25B 3.22B 2.69B 2.98B 1.57B 1.97B 2.46B 1.96B 1.27B 1.54B
INR 12.59B 10.56B 9.2B 8.17B 0 0 6.54B 4.68B 3.84B 4.72B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 15.13B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.